References
1. Dan GA, Martinez-Rubio A, Agewall S, et al. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018;20(5):731-732an.
2. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e272-e391.
Figure 1A. Electrocardiogram performed between episodes of non-sustained polymorphic ventricular tachycardia: atrial fibrillation with controlled ventricular rate, flattened T waves and slightly prolonged corrected QT interval.
Figure 1B. Electrocardiogram performed between episodes of sustained polymorphic ventricular tachycardia: sinus rhythm, note the extreme corrected QT interval prolongation (more than 700 milliseconds) and the presence of T-wave alternans (white stars).
Figure 1C. Electrocardiogram performed during drugs’ washout; note the shorter QT interval.